The facility is to be operational by the third quarter of 2009 and will be located at the site of the Netherlands Vaccine Institute at Bilthoven, The Netherlands.
The greenfield facility will produce a range of vaccines to treat the population of The Netherlands. Vaccine bulk products will be formulated and filled in vials and syringes at the new sterile production facility. Operations will include freeze drying of vials, inspection, labeling, packaging, and storage. A second part of the building will house a central sterilization department for the complete site.
Jacobs' conceptual design will embed the latest developments in vaccine production to satisfy Dutch regulations and FDA/EMEA requirements, as well as reflect recent benchmarks and a design-to-cost approach.
In making the announcement, Jacobs Group Vice President Andy Kremer stated, "This challenging assignment is an excellent opportunity to further develop our relationship with both NVI and RGD. We are enthusiastic about becoming their partner for this vital public health project."
NVI CEO Thijs Veerman said, "The project will result in a modern, state-of-the art facility to continue vaccine manufacturing at the highest compliance level."
Jacobs, with over 42,000 employees and revenues approaching $7.0 billion, provides technical, professional, and construction services globally.
Any statements made in this release that are not based on historical fact are forward-looking statements. Although such statements are based on management's current estimates and expectations, and currently available competitive, financial, and economic data, forward-looking statements are inherently uncertain. We, therefore, caution the reader that there are a variety of factors that could cause business conditions and results to differ materially from what is contained in our forward-looking statements. For a description of some of the factors which may occur that could cause actual results to differ from our forward-looking statements please refer to our 2005 Form 10-K, and in particular the discussions contained under Items 1 - Business, 3 - Legal Proceedings, and 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations. We also caution the readers of this release that we do not undertake to update any forward-looking statements made herein.
For additional information contact: Rod Sharp 626.578.6992
Source: Jacobs Engineering Group Inc.
